Global Deferoxamine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Deferoxamine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Deferoxamine (DFOA), sold under the brand name Desferal, is a medication that binds iron and aluminium. It is specifically used in iron overdose, hemochromatosis either due to multiple blood transfusions or an underlying genetic condition, and aluminium toxicity in people on dialysis. It is used by injection into a muscle, vein, or under the skin
Deferoxamine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Deferoxamine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Aluminum Overload and Chronic Iron Overload are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Deferoxamine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Deferoxamine key manufacturers include APP Pharmaceuticals, Hospira, Watson Laboratories, Novartis Pharmaceuticals, Fresenius Kabi, Gland Pharma, West-Ward Pharms and Novartis, etc. APP Pharmaceuticals, Hospira, Watson Laboratories are top 3 players and held % sales share in total in 2022.
Deferoxamine can be divided into Injection for Solution, Powder for Solution and Lyophilized for Solution,, etc. Injection for Solution is the mainstream product in the market, accounting for % sales share globally in 2022.
Deferoxamine is widely used in various fields, such as Aluminum Overload, Chronic Iron Overload, Chronic Aluminum Overload and Acute Iron Intoxication, etc. Aluminum Overload provides greatest supports to the Deferoxamine industry development. In 2022, global % sales of Deferoxamine went into Aluminum Overload filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Deferoxamine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
APP Pharmaceuticals
Hospira
Watson Laboratories
Novartis Pharmaceuticals
Fresenius Kabi
Gland Pharma
West-Ward Pharms
Novartis
Segment by Type
Injection for Solution
Powder for Solution
Lyophilized for Solution
Aluminum Overload
Chronic Iron Overload
Chronic Aluminum Overload
Acute Iron Intoxication
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Deferoxamine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Deferoxamine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Deferoxamine industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Deferoxamine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Deferoxamine introduction, etc. Deferoxamine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Deferoxamine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Deferoxamine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Deferoxamine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Aluminum Overload and Chronic Iron Overload are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Deferoxamine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Deferoxamine key manufacturers include APP Pharmaceuticals, Hospira, Watson Laboratories, Novartis Pharmaceuticals, Fresenius Kabi, Gland Pharma, West-Ward Pharms and Novartis, etc. APP Pharmaceuticals, Hospira, Watson Laboratories are top 3 players and held % sales share in total in 2022.
Deferoxamine can be divided into Injection for Solution, Powder for Solution and Lyophilized for Solution,, etc. Injection for Solution is the mainstream product in the market, accounting for % sales share globally in 2022.
Deferoxamine is widely used in various fields, such as Aluminum Overload, Chronic Iron Overload, Chronic Aluminum Overload and Acute Iron Intoxication, etc. Aluminum Overload provides greatest supports to the Deferoxamine industry development. In 2022, global % sales of Deferoxamine went into Aluminum Overload filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Deferoxamine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
APP Pharmaceuticals
Hospira
Watson Laboratories
Novartis Pharmaceuticals
Fresenius Kabi
Gland Pharma
West-Ward Pharms
Novartis
Segment by Type
Injection for Solution
Powder for Solution
Lyophilized for Solution
Segment by Application
Aluminum Overload
Chronic Iron Overload
Chronic Aluminum Overload
Acute Iron Intoxication
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Deferoxamine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Deferoxamine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Deferoxamine industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Deferoxamine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Deferoxamine introduction, etc. Deferoxamine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Deferoxamine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices